Neurocrine Biosciences Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neurocrine Biosciences (NBIX) Misses Q1 EPS by 5c
May 5, 2021 4:29 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.49, $0.05 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $236.6 million versus the consensus estimate of $252.55 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More